Skip to content

Clinical trials

Microscopic Polyangiitis trials in Canada

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Microscopic Polyangiitis Country / region: Canada Clear all

15 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20061
20102
20111
20133
20161
20171
20181
20191
20201
20211
20241
20251

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed7
Recruiting4
Unknown status2
Active, not recruiting1
Terminated1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
University of Pennsylvania5
Cambridge University Hospitals NHS Foundation Trust1
Christian Pagnoux1
Human Genome Sciences Inc., a GSK Company1
InflaRx GmbH1
McGill University Health Centre/Research Institute of the McGill University Health Centre1
Novartis Pharmaceuticals1
Ottawa Hospital Research Institute1
Peter Merkel1
University of British Columbia1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Granulomatosis with Polyangiitis15
Microscopic Polyangiitis15
Vasculitis8
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis7
Churg-Strauss Syndrome7
Polyarteritis Nodosa6
Takayasu Arteritis5
Giant Cell Arteritis4
IgA Vasculitis2
Systemic Vasculitis2

Trials

Showing 51 to 15 of 15. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.